Posts from: korinek

MTEC Awards $3M to Astrocyte Pharmaceuticals for Clinical Study of AST-004

Groton, CT, September 16, 2021 – Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel neuroprotective therapeutics for the treatment of neurodegenerative brain injuries,...

Astrocyte Pharmaceuticals Awarded Major Grant to Further Develop Promising Treatment for Brain Injury

Groton, CT, September 8, 2021 – Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel neuroprotective therapeutics for the treatment of brain injuries, announced...

Lisa Manna Joins Astrocyte Pharmaceuticals as Vice President of Clinical Development Operations

Lisa Manna, RN, MBA Groton, CT, July 1, 2021 – Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel neuroprotective therapeutics for the treatment of neurodegenerative...

Astrocyte Pharmaceuticals Raises $6M Series A to Advance Next Generation Stroke and TBI Treatment to the Clinic

Astrocyte Pharmaceuticals

Groton, CT, May 3, 2021 – Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel neuroprotective therapeutics for the treatment of neurodegenerative brain injuries,...

Astrocyte Pharmaceuticals Announces Expanded Clinical Advisory Board

Groton, CT, December 1, 2020 – Astrocyte Pharmaceuticals Inc., a privately held pharmaceutical company advancing neuroprotective treatments, announced the establishment of its Clinical Advisory Board...

Astrocyte Pharmaceuticals Presents NHP Stroke Study at International Stroke Conference

Cambridge, MA, February 21, 2020 – Astrocyte Pharmaceuticals Inc. presented the results of a key preclinical efficacy study today at the International Stroke Conference in Los Angeles demonstrating...

Jeffrey L. Saver to Chair Astrocyte Pharmaceuticals’ Clinical Advisory Board

Cambridge, MA, December 11, 2018 – Astrocyte Pharmaceuticals Inc., a privately held pharmaceutical company, today announced that Jeffrey L. Saver, M.D., has joined the company’s Scientific Advisory...

Astrocyte Pharmaceuticals Completes $2.3M Pre-A Financing Round

Cambridge, MA, June 6, 2018 – Astrocyte Pharmaceuticals Inc. announced today that it has completed a Pre-A financing round that raised over $2.3M.  The company is advancing several small molecule neuroprotective...

Astrocyte Pharmaceuticals Awarded $3M NIH Small Business Grant to Advance TBI and Concussion Therapeutic

Cambridge, MA, September 19, 2018 – Astrocyte Pharmaceuticals Inc., a privately held pharmaceutical company, announced today that it has been awarded a $3 million Phase 2 Small Business Innovation Research...

Astrocyte Pharmaceuticals Awarded Alzheimer’s Disease Research Grant

Cambridge, MA, September 18, 2018 – Astrocyte Pharmaceuticals, Inc., a privately held pharmaceutical company, announced today that it has been awarded $287k Phase 1 Small Business Technology Transfer...

Developing innovative neuroprotection therapies for Traumatic Brain Injuries (TBI), concussions, stroke, and neurodegenerative disorders